At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 381 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
IPX066 95 mg LDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
In Brief
A Phase 3 clinical trial evaluating Placebo, IPX066 95 mg LD, and 3 other interventions for Parkinson's Disease. Completed, enrolled 381 participants across 60 sites in 7 countries.
Detailed Summary
This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesCanada, Estonia, Latvia, Lithuania, Romania, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionOct 2010
Study CompletionNov 2010
TodayJul 2026
First PostedApr 14, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.2 years ago
Interventions
Placebodrug
Placebo
IPX066 95 mg LDdrug
IPX066 capsule containing 95 mg LD/23.75 mg CD
IPX066 145 mg LDdrug
IPX066 capsule containing 145 mg LD/36.25 mg CD
IPX066 195 mg LDdrug
IPX066 capsule containing 195 mg LD/48.75 mg CD
IPX066 245 mg LDdrug
IPX066 capsule containing 245 mg LD/61.25 mg CD